CD7 and acute lymphoblastic leukemia: This approach has been considered in an ongoing Phase I clinical trial (NCT03690011) which was based on the investigation of the effects related to the presence of CD7-CRISPR-Cas9-edited CD7 CAR-T cells in patients with CD7+ T-cell malignancies, including T-ALL [99].